Sodium Picosulfate
(Synonyms: 匹可硫酸钠; Sodium Picosulphate) 目录号 : GC16452
匹可硫酸钠抑制水和电解质的吸收，并增加它们的分泌。
Cas No.:10040-45-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sodium Picosulfate is a laxative.
Sodium Picosulfate is a laxative that inhibits water and electrolytes absorption and increases their secretion. In cultured human, rat and rabbit liver cells, sodium picosulfate (1600 μg/ml) reduced the protein content in rabbit liver cells. Also, hepatocytes of rabbit were more sensitive to sodium picosulfate [1].
In patients underwent a barium enema, sodium picosulphate reduced the serum concentrations of sodium, potassium and urea by 1.299, 0.163 and 0.556, respectively [2]. In patients with morphine sulphate induced constipation, sodium picosulfate was well-tolerated and significantly improved constipation with normal stool consistency, not requiring suppositories, manual evacuation or enemas [3]. In patients with chronic constipation, sodium picosulphate (7 mg) improved stool frequency and straining in 82.8% patients and reduced bloating [4].
References:
[1]. Nishikawa J, Kast A. Effects of sodium picosulfate, bisacodyl and sennoside in cultured human, rat and rabbit liver cells. Arzneimittelforschung, 1981, 31(6): 1010-1013.
[2]. Ryan F, Anobile T, Scutt D, et al. Effects of oral sodium picosulphate Picolax on urea and electrolytes. Nurs Stand, 2005, 19(45): 41-45.
[3]. Twycross RG, McNamara P, Schuijt C, et al. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med, 2006, 20(4): 419-423.
[4]. Wulkow R, Vix JM, Schuijt C, et al. Randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of the acute use of sodium picosulphate in patients with chronic constipation. Int J Clin Pract, 2007, 61(6): 944-950.
| Cas No. | 10040-45-6 | SDF | |
| 别名 | 匹可硫酸钠; Sodium Picosulphate | ||
| 化学名 | disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate | ||
| Canonical SMILES | C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+] | ||
| 分子式 | C18H15NO8S2.2Na | 分子量 | 481.41 |
| 溶解度 | ≥ 13.05mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0772 mL | 10.3862 mL | 20.7723 mL |
| 5 mM | 0.4154 mL | 2.0772 mL | 4.1545 mL |
| 10 mM | 0.2077 mL | 1.0386 mL | 2.0772 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。